Assuming the underwriter’s overallotment option of 2.1M shares is exercised, there will be 15.9M new shares in all. ANDS had 29.4M* basic shares outstanding prior to the financing, so this deal incurs an expansion of more than 50% in the share count.
mcbio and I have been critical of ANDS’ management’s pump & dump style (#msg-52795076), and skeptical of its purportedly best-in-class HCV non-nuke (#msg-50635544). Today’s financing deal does nothing to change that assessment.
*ANDS has about 7M additional shares on a fully-diluted basis, but many are from options that are far out of the money and don’t figure prominently in a valuation analysis.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.